- Home
- TVGN
as 11-21-2024 4:00pm EST
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 53.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $21.09 | Next Earning Date: | 11-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tevogen Bio Holdings Inc. Common Stock News
TVGN Breaking Stock News: Dive into TVGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
GlobeNewswire
2 days ago
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
GlobeNewswire
7 days ago
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
GlobeNewswire
7 days ago
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
GlobeNewswire
13 days ago
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
GlobeNewswire
16 days ago
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
GlobeNewswire
17 days ago
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
GlobeNewswire
17 days ago
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
Compare TVGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVGN Tevogen Bio Holdings Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.